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acute	 respiratory	 infection	 (extended	SARI)	or	an	acute	 respiratory	 infection	 (ARI)	
case	definition	was	used	that	did	not	require	fever	as	a	criterion.
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and	 consequently	may	miss	 up	 to	 a	 significant	 proportion	 of	 RSV	
infections	especially	in	younger	children.12-14	In	2016,	WHO	piloted	
a	 RSV	 surveillance	 strategy	 that	 leverages	 the	 capacities	 of	 the	










participated	 in	 the	 pilot	 study.	 Countries	were	 selected	 based	 on	
having	a	WHO‐designated	National	 Influenza	Centre	and/or	a	na-





2.1 | Site profile and surveillance practices
In	 Argentina,	 Brazil,	 Chile,	 Egypt,	 Russian	 Federation,	 and	 South	
Africa,	 patients	 admitted	 to	 sentinel	 hospitals	 were	 screened	
across	all	ages,	whereas	 in	Australia	and	Canada	pediatric	hospital	
admissions	 only	 were	 screened.	 In	 Côte	 d'Ivoire,	 India,	 Mongolia,	
Mozambique,	and	Thailand,	patients	were	screened	across	all	ages	
in	 both	 sentinel	 hospitals	 and	 outpatient	 clinics.	 In	 the	 United	
Kingdom,	patients	were	screened	across	all	ages	attending	sentinel	
TA B L E  1  Sentinel	site	profile,	WHO	RSV	surveillance,	2017‐18
 
Age‐group under 





Argentina All	ages Inpatient 6 2016	wk52 1214	(99%)
Australia 0‐18	y Inpatient 1 2017	wk31 1560	(100%)
Brazil All	ages Inpatient 2 2017	wk03 727	(91%)
Canada 0-16 y Inpatient 12 2017	wk34 2178a	(100%)
Chile All	ages Inpatient 2 2017	wk01 883	(100%)
Côte	d'Ivoire All	ages Inpatient	+	Outpatient 9 2017	wk01 1772	(36%)
Egypt All	ages Inpatient 4 2017	wk01 1194	(100%)
India All	ages Inpatient	+	Outpatient 11 2017	wk01 1537	(82%)
Mongolia All	ages Inpatient	+	Outpatient 7 2017	wk02 1175	(89%)
Mozambique All	ages Inpatient	+	Outpatient 4 2017	wk01 969	(76%)
Russian	Federation All	ages Inpatient 18 2016	wk52 1648	(100%)
South	Africa All	ages Inpatient 5 2017	wk01 3409	(100%)
Thailand All	ages Inpatient	+	Outpatient 11 2017	wk01 2752	(53%)
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General	Practitioner	clinics,	as	well	as	children	under	5	years	in	sen-
tinel	hospitals	 in	England	 (Table	1).	Canada	 reported	data	only	 for	
those	patients	who	tested	RSV	positive	and	was	excluded	from	the	
analysis.	The	number	and	type	of	sentinel	hospitals	(secondary	and	







shortness	 of	 breath,	 or	 runny	 nose.	 Sepsis	 and	 apnea	 were	 also	
criteria	 for	enrollment	 in	 infants	<6	months	 (Table	2).	Additionally,	
information	on	 fever,	wheeze,	 and	associated	 risk	 factors,	 such	as	
prematurity,	 malnutrition,	 cardiac	 and	 respiratory	 illness,	 and	 im-
munodeficiency,	 were	 recorded	 on	 a	 standardized	 case	 record	













ing	 of	 contemporary	 and	 historical	 strains	 of	 RSV‐A	 and	 RSV‐B	 or	
panels	supplied	by	Quality	Control	for	Molecular	Diagnostics	(QCMD),	
United	Kingdom.	Specimens	received	by	laboratories	were	stored	at	







or	 in‐house	 laboratory	developed	 tests	 (LDTs)	provided	 these	were	




data	platform	was	adapted	 to	 receive	 case‐based	 clinical	 and	 labo-
ratory	RSV	data,	and	countries	were	required	to	upload	anonymized	
RSV	surveillance	data	every	week	or	every	fortnight.	Public	access	to	





epidemiological	week	 (EW)	 52	 of	 2016	 to	 EW	39	of	 2017)	with	
11	 of	 14	 countries	 initiating	 surveillance	 in	 the	 first	 quarter	 of	
2017.	 The	 end	date	 for	 this	 analysis	was	 set	 at	 EW	39	of	 2018.	
England	 reported	data	only	 from	 their	General	Practitioner	 sen-
tinel	surveillance	(Table	1).	All	analyses	were	done	separately	for	
inpatient	 and	 outpatient	 surveillance	 and	 disaggregated	 into	 six	
age‐groups—<6	months,	 6	months	 to	 <2	 years,	 2	 to	 <5	 years,	 5	
to	<18	years,	18	to	<65	years,	and	65	years	and	more.	Univariate	
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logistic	 regression	was	 used	 to	 determine	 clinical	 predictors	 for	





was	 calculated	 for	 the	 age‐specific	 percent	 positivity	 cumulated	
over	 the	 study	 period.	We	 also	 evaluated	 the	 individual	 perfor-
mance	 of	 apnea	 and	 sepsis	 (for	 infants	 <6	 months),	 and	 when	






















est	 (37%)	 in	 infants	 <6	 months,	 25%	 in	 children	 6	 months	 to	
2	years,	and	12%	in	children	2‐5	years	age.	RSV	percent	positiv-
ity	was	 about	 4%	 in	 adults	 and	older	 adults	 aged	65	 years	 and	
more.	RSV	percent	positivity	was	 lower	but	showed	similar	age	
trends	 amongst	 non‐hospitalized	 patients.	 In	 contrast,	 percent	
positivity	for	influenza	amongst	hospitalized	patients	was	3%‐7%	
in	 children	 <2	 years,	 11%	 in	 adults	 aged	 18	 to	 <65	 years,	 and	
14%	in	older	adults	aged	over	65	years	(Figure	2).	The	age‐group	




ized	 and	 non‐hospitalized	 patients	 across	 all	 the	 participating	
countries	(Figure	3).
Amongst	 hospitalized	 patients	 <6	 months,	 apnea	 was	 signifi-
cantly	 more	 prevalent	 amongst	 RSV‐positive	 infants	 (8.3%)	 than	
those	 who	 tested	 negative	 (6.0%)	 (odds	 ratio	 (OR)	 1.42;	 95%	 CI:	
1.05‐1.94)	 (Table	 4).	 Sepsis	 was	 less	 common	 amongst	 RSV‐posi-
tive	infants	(4.7%)	than	those	who	tested	negative	(10%)	(OR	‐	0.44;	
95%	CI:	0.31‐0.64).	Cough	(OR:	6.21,	95%	CI:	4.77‐8.08),	shortness	







cantly	 less	 likely	 amongst	 RSV	 cases	 than	 RSV‐negative	 children	
<2	years	than	in	those	aged	6	months	to	2	years.	Similar	trends	 in	









F I G U R E  1  Age	distribution	of	
specimens	tested,	WHO	RSV	surveillance,	
2017‐18
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3.2 | Case definition
Amongst	 hospitalized	 infants	 <6	 months	 age,	 29%	 of	 those	 RSV	
cases	that	otherwise	had	been	captured	by	an	extended	SARI	case	
















































0	to	<6	m 2493	(20.5) 1461	(49.3) 3954	(26.2) 157	(3.3) 40	(9.9) 197	(3.9)
6	m	to	<2	y 3456	(28.5) 1137	(38.3) 4593	(30.4) 726	(15.6) 157	(38.9) 883	(17.5)
2	to	<5	y 1365	(11.2) 187	(6.3) 1552	(10.3) 579	(12.5) 93	(23.0) 672	(13.3)
5	to	<18	y 1077	(8.8) 49	(1.6) 1126	(7.4) 768	(16.6) 19	(4.7) 787	(15.6)
18	to	<65	y 2546	(21.0) 74	(2.5) 2620	(17.3) 1991	(43.0) 74	(18.8) 2065	(41.0)
65+	y 1175	(9.7) 55	(1.8) 1230	(8.1) 405	(8.7) 20	(4.9) 425	(8.4)
Male 6255	(53.3) 1565	(53.9) 7820	(53.4) 1241	(52.7) 160	(57.5) 1401	(53.2)
F I G U R E  2  Age	distribution	and	
percent	positivity	of	RSV	and	influenza,	
2017‐18
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F I G U R E  3  A,	RSV	and	influenza	proportion	positive	(inpatient	surveillance),	2017‐18.	B,	RSV	and	influenza	proportion	positive	
(outpatient	surveillance),	2017‐18
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Odds ratio (95% CI)
Outpatient surveillance
Univariate










Apnea 103	(6.0) 75	(8.3) 1.42	(1.05‐1.94) 0	(0) 0	(0) –
Sepsis 166	(10.0) 37	(4.7) 0.44	(0.31‐0.64) 0	(0) 0	(0) –
Cough 1813	(76.3) 1343	(95.2) 6.21	(4.77‐8.08) 147	(93.6) 37	(92.5) 0.83	(0.21‐3.20)
Shortness	of	breath 643	(49.3) 531	(61.6) 1.64	(1.38‐1.96) 17	(11.2) 9	(28.1) 3.08	(1.22‐7.74)
Fever	(history) 1044	(53.4) 503	(45.9) 0.74	(0.63‐0.86) 127	(81.9) 26	(76.4) 0.71	(0.29‐1.74)
Fever	(≥38°C) 1718	(76.8) 847	(68.8) 0.66	(0.57‐0.77) 19	(38.7) 4	(80.0) 6.31	(0.65‐60.8)
Wheeze 669	(32.0) 527	(45.0) 1.73	(1.49‐2.01) 2	(1.5) 3	(10) 6.94	(1.10‐43.5)
Runny	nose 856	(44.1) 590	(58.0) 1.75	(1.50‐2.04) 2	(5.8) 2	(66.6) 32.0	(1.95‐522.7)
Lower	chest	in‐drawing 717	(41.5) 525	(63.6) 2.46	(2.07‐2.91) 0	(0) 1	(50) –
Pre‐existing	conditiona 453	(18.1) 190	(7.9) 0.67	(0.56‐0.80) 6	(4.0) 0	(0) –
Children	(6	m	to	<2	y)
Cough 3170	(93.5) 1066	(96.5) 1.92	(1.35‐2.74) 656	(91.2) 140	(90.3) 0.89	(0.49‐1.62)
Shortness	of	breath 1483	(57.9) 565	(65.7) 1.39	(1.18‐1.63) 92	(13.8) 27	(20.3) 1.58	(0.98‐2.55)
Fever	(history) 1858	(65.6) 597	(61.7) 0.84	(0.72‐0.98) 583	(82.3) 126	(82.3) 1.00	(0.63‐1.58)
Fever	(≥38°C) 2188	(71.6) 691	(69.3) 0.89	(0.76‐1.04) 162	(54.9) 37	(77.0) 2.76	(1.35‐5.62)
Wheeze 1102	(38.7) 384	(41.1) 1.10	(0.94‐1.28) 38	(6.6) 14	(10.6) 1.67	(0.87‐3.18)
Sore	throat 629	(27.6) 218	(32.2) 1.24	(1.03‐1.49) 101	(15.7) 21	(16.9) 1.09	(0.65‐1.82)
Runny	nose 1167	(49.4) 472	(61.3) 1.61	(1.36‐1.90) 22	(13.9) 3	(21.4) 1.68	(0.43‐6.52)
Lower	chest	in‐drawing 904	(42.4) 343	(56.4) 1.75	(1.46‐2.10) 6	(9.0) 3	(30.0) 4.28	(0.87‐21.0)
Pre‐existing	conditiona 590	(17.0) 183	(9.5) 0.93	(0.77‐1.11) 17	(2.6) 6	(4.8) 1.86	(0.72‐4.83)
Children	(2	to	<5	y)
Cough 1250	(92.8) 172	(93.4) 1.10	(0.59‐2.04) 542	(95.0) 86	(96.6) 1.48	(0.44‐4.97)
Shortness	of	breath 586	(54.3) 90	(54.2) 0.99	(0.71‐1.38) 57	(12.0) 14	(19.4) 1.75	(0.92‐3.35)
Fever	(history) 736	(64.7) 98	(60.4) 0.83	(0.59‐1.16) 459	(81.2) 77	(83.7) 1.18	(0.65‐2.14)
Fever	(≥38°C) 940	(75.5) 121	(71.6) 0.81	(0.57‐1.17) 182	(70.5) 36	(85.7) 2.50	(1.01‐6.19)
Wheeze 386	(34.0) 60	(36.5) 1.11	(0.79‐1.56) 33	(7.8) 10	(14.0) 1.92	(0.90‐4.09)
Sore	throat 303	(31.8) 43	(34.9) 1.15	(0.77‐1.70) 123	(27.1) 25	(39.6) 1.76	(1.02‐3.04)
Runny	nose 414	(48.3) 60	(50.8) 1.10	(0.75‐1.62) 16	(14.2) 2	(28.5) 2.40	(0.42‐13.4)
Lower	chest	in‐drawing 277	(36.8) 47	(45.6) 1.43	(0.95‐2.17) 8	(13.7) 0	(0) –
Pre‐existing	conditiona 305	(22.3) 33	(9.5) 0.74	(0.50‐1.10) 23	(5.0) 3	(4.7) 0.93	(0.27‐3.20)
Children	(5	to	<18	y)
Cough 929	(86.7) 45	(91.8) 1.71	(0.60‐4.85) 693	(96.1) 16	(84.2) 0.21	(0.05‐0.78)
Shortness	of	breath 471	(44.3) 24	(48.9) 1.20	(0.67‐2.13) 87	(17.1) 4	(30.7) 2.14	(0.64‐7.10)
Fever	(history) 600	(66.0) 21	(45.6) 0.43	(0.23‐0.78) 635	(85.4) 17	(89.4) 1.44	(0.32‐6.34)
Fever	(≥38°C) 669	(69.6) 27	(62.7) 0.73	(0.39‐1.38) 237	(77.2) 4	(100.0) –
Wheeze 178	(18.9) 9	(19.5) 1.04	(0.49‐2.19) 30	(6.9) 1	(8.3) 1.20	(0.15‐9.68)
Sore	throat 350	(37.6) 8	(23.5) 0.50	(0.22‐1.13) 218	(48.0) 2	(18.1) 0.24	(0.05‐1.12)
Runny	nose 197	(36.4) 15	(57.6) 2.38	(1.07‐5.28) 21	(16.6) 0	(0) –
Lower	chest	in‐drawing 95	(22.8) 13	(52.0) 3.66	(1.61‐8.28) 0	(0) 1	(100) –
Pre‐existing	conditiona 158	(14.6) 13	(8.6) 2.10	(1.08‐4.04) 21	(4.6) 1	(9.0) 2.06	(0.25‐16.8)
Adults	(18	to	<65	y)
Cough 2326	(92.3) 71	(95.9) 1.95	(0.60‐6.26) 1746	(96.2) 64	(94.1) 0.63	(0.22‐1.78)
(Continues)
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Surveillance	 confirmed	 the	 high	 burden	 of	 RSV	 in	 children	
<2	 years,	 especially	 in	 infants	 <6	 months.7,18‐20	 RSV	 commonly	
manifests	 clinically	 in	 infants	 with	 bronchiolitis.21-23	 Wheeze	 has	
been	one	of	 the	clinical	end	points	of	 interest	 to	evaluate	vaccine	
efficacy	 trials.24	 From	 a	 surveillance	 case	 definition	 perspective,	
including	wheeze	 as	 a	 criteria	 reduces	 its	 sensitivity	 in	 children.25 
Apnea,	 though	 it	 lacked	 sensitivity,	 was	 a	 significant	 clinical	 pre-






Countries	 reported	 challenges	 in	 the	 adoption	 of	 the	 extended	
SARI	 case	 definition	 in	 the	 early	 stages	 of	 the	 RSV	 surveillance	
which	 were	 resolved	 through	 training.	 In	 practice,	 the	 physician	
or	nurse	 in	a	 sentinel	hospital	 engaged	 in	both	RSV	and	 influenza	
surveillance,	 screened	 patients	 with	 acute	 onset	 cough	 or	 short-
ness	of	breath,	and	collected	an	appropriate	respiratory	specimen.	
Information	on	 the	presence	or	 absence	of	 fever	was	 recorded	 in	
the	 specimen	 requisition	 form	 and	 sent	 to	 the	 laboratory	 along	
with	the	respiratory	specimen.	At	the	laboratory,	all	the	specimens	
were	tested	for	RSV,	whereas	those	specimens	from	patients	with	
fever	were	additionally	 tested	 for	 influenza.	Moreover,	 the	 results	
for	 influenza	were	reported	to	FluNet	only	for	those	patients	with	
fever.	Notwithstanding	the	additional	burden	of	reporting,	this	en-
sured	 that	 the	RSV	 surveillance	 did	 not	 disturb	 the	 influenza	 sur-
veillance	 system	 but	 complemented	 it	 by	 targeting	 a	 very	 young	
age‐group	that	is	important,	yet	often	underrepresented	in	influenza	
surveillance.
The	 WHO	 RSV	 surveillance	 pilot	 had	 several	 limitations,	
and	 its	early	findings	need	to	be	 interpreted	with	some	caveats.	
Generalization	of	the	findings	should	be	made	with	caution.	First,	
the	 number,	 type,	 and	 selection	 of	 sentinel	 sites	 varied	 across	
countries	and	were	generally	not	designed	to	be	nationally	repre-
sentative	or	comparable	in	terms	of	the	clinical	severity	of	patients	
included.	 Second,	 the	 strategy	 for	 sampling	 patients	 for	 testing	
varied	across	sentinel	sites.	This	would	need	to	be	accounted	for	
when	estimating	disease	burden	from	surveillance	data	but	 is	of	
no	 consequence	 for	 this	 analysis.	 Third,	 Brazil	 faced	 a	 shortfall	
of	extended	SARI	cases	and	had	to	bridge	the	gap	with	patients	
sourced	from	SARI	surveillance.	However,	with	over	20	000	pa-
tients	 from	 all	 countries	 pooled	 together,	 the	 bias	 in	 evaluating	
the	performance	of	fever	as	a	criterion	for	detecting	RSV	would	
be	 small.	 Fourth,	 the	 PPV	 is	 likely	 to	 be	 higher	 during	 the	 RSV	
season,	but	 it	was	beyond	 the	scope	of	 this	analysis	 to	 robustly	





Odds ratio (95% CI)
Outpatient surveillance
Univariate









Shortness	of	breath 1351	(53.8) 39	(54.1) 1.01	(0.63‐1.62) 572	(50.6) 21	(41.1) 0.68	(0.38‐1.20)
Fever	(history) 1493	(84.4) 43	(79.6) 0.72	(0.36‐1.41) 1592	(88.8) 53	(80.3) 0.51	(0.27‐0.95)
Fever	(≥38°C) 2051	(94.3) 47	(85.4) 0.35	(0.16‐0.76) 353	(83.2) 20	(83.3) 1.00	(0.33‐3.03)
Wheeze 432	(17.8) 9	(12.5) 0.65	(0.32‐1.33) 184	(22.8) 7	(16.6) 0.67	(0.29‐1.54)
Sore	throat 799	(41.7) 20	(35.0) 0.75	(0.43‐1.31) 387	(61.4) 17	(48.5) 0.59	(0.29‐1.17)
Runny	nose 388	(40.6) 10	(52.6) 1.62	(0.65‐4.02) 43	(29.0) 2	(28.5) 0.97	(0.18‐5.22)
Lower	chest	in‐drawing 70	(12.1) 2	(28.5) 2.90	(0.55‐15.2) 0	(0) 1	(16.6) –
Pregnant 148	(9.0) 1	(2.3) 0.23	(0.03‐1.75) 12	(2.5) 2	(8.0) 3.34	(0.70‐15.8)
Pre‐existing	conditionb 860	(33.7) 31	(41.8) 1.41	(0.88‐2.25) 61	(9.5) 3	(8.3) 0.86	(0.25‐2.89)
Older	adults	(65+	y)
Cough 1065	(92.1) 51	(92.7) 1.08	(0.38‐3.08) 359	(97.8) 17	(94.4) 0.37	(0.04‐3.20)
Shortness	of	breath 763	(66.1) 39	(70.9) 1.24	(0.68‐2.25) 146	(74.4) 9	(75.0) 1.02	(0.26‐3.94)
Fever	(history) 423	(62.2) 24	(58.5) 0.85	(0.45‐1.62) 308	(94.4) 16	(100) –
Fever	(≥38°C) 896	(83.8) 36	(75.0) 0.57	(0.29‐1.13) 34	(82.9) 0	(0) –
Wheeze 298	(27.2) 22	(40.0) 1.78	(1.02‐3.10) 54	(47.7) 2	(40.0) 0.72	(0.11‐4.52)
Sore	throat 242	(29.9) 10	(24.3) 0.75	(0.36‐1.56) 35	(58.3) 1	(33.3) 0.35	(0.03‐4.15)
Runny	nose 107	(38.6) 7	(36.8) 0.92	(0.35‐2.42) 7	(36.8) 0	(0) –
Lower	chest	in‐drawing 62	(19.8) 6	(30.0) 1.72	(0.63‐4.67) 0	(0) 0	(0) –
Pre‐existing	conditionb 762	(64.8) 37	(67.2) 1.11	(0.62‐1.98) 21	(31.8) 1	(33.3) 1.07	(0.09‐12.4)
aPre‐existing	condition	includes	prematurity,	chronic	respiratory	disease	including	asthma,	malnutrition,	or	immunodeficiency.	
bPre‐existing	condition	includes	respiratory	disease,	diabetes,	heart	disease,	or	immunodeficiency.	
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71%	(69‐73) 20%	(18	−21) 34%	(32‐36) 0.31 71%	(51‐86) 15%	(10‐22) 13%	(8‐20) 0.43
Apnea 8.3%	(6‐10) 93%	(92‐95) 42%	(34‐49) 0.51 – – –  
Sepsis 4.7%	(3‐6) 89%	(88‐91) 18%	(13‐24) 0.47 – – –  




82%	(80‐84) 16%	(15‐17) 24%	(23‐26) 0.32 83%	(76‐89) 11%	(8‐13) 15%	(12‐18) 0.47




80%	(74‐85) 16%	(14‐18) 11%	(9‐13) 0.29 92%	(82‐97) 9.9%	(7‐13) 12%	(9‐15) 0.51




77%	(63‐87) 18%	(15‐20) 4%	(2‐5) 0.21 81%	(48‐97) 8.3%	(6‐11) 2%	(1‐4) 0.45




89%	(79‐94) 6.6%	(5‐7) 2%	(2‐3) 0.47 86%	(70‐95) 16%	(13‐19) 5%	(3‐7) 0.51




78%	(64‐87) 15%	(13‐17) 4%	(3‐5) 0.46 66%	(9‐99) 27%	(17‐39) 4%	(0.6‐14) 0.46
Ex‐SARI/ARI	+	wheeze 40%	(27‐54) 74%	(72‐77) 6%	(4‐10) 0.57 0%	(0‐70) 98%	(91‐99) – 0.49
Abbreviations:	ARI,	acute	respiratory	infection;	AUC,	area	under	curve;	CI,	confidence	interval;	Ex‐SARI,	extended	severe	acute	respiratory	infection;	
ILI,	influenza‐like	illness;	PPV,	positive	predictive	value;	SARI,	severe	acute	respiratory	infection.
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2016,	and	June	2016	that	led	to	the	development	of	the	WHO	RSV	
surveillance	 strategy,	 and	 in	 the	 project	 review	 meetings	 held	 in	
December	2017	and	October	2018.	We	are	grateful	to	the	National	
Influenza	Centres,	Public	Health	Laboratories	and	the	Ministries	of	




for	 providing	 support	 as	 RSV	 reference	 laboratories	 for	 this	 pro-
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